Keros Therapeutics, Inc. (KROS)
- Previous Close
49.45 - Open
49.45 - Bid 48.57 x 200
- Ask 48.76 x 100
- Day's Range
47.88 - 49.45 - 52 Week Range
27.02 - 73.00 - Volume
144,464 - Avg. Volume
306,485 - Market Cap (intraday)
1.757B - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-5.15 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
90.63
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
www.kerostx.comRecent News: KROS
Performance Overview: KROS
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KROS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KROS
Valuation Measures
Market Cap
1.76B
Enterprise Value
1.33B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.51k
Price/Book (mrq)
3.87
Enterprise Value/Revenue
5.68k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.79%
Return on Equity (ttm)
-39.63%
Revenue (ttm)
234k
Net Income Avi to Common (ttm)
-160.3M
Diluted EPS (ttm)
-5.15
Balance Sheet and Cash Flow
Total Cash (mrq)
442.44M
Total Debt/Equity (mrq)
3.13%
Levered Free Cash Flow (ttm)
-90.18M